



Company Overview

Intellipharmaeutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Intellipharmaeutics has developed several drug delivery systems based on this technology platforms, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505 (b)(2) drug delivery product candidates in its development pipeline in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

Intellipharmaeutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.

Sep 5 2019, 1:33 PM EDT

Intellipharmaeutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.

Aug 15 2019, 3:15 PM EDT

Intellipharmaeutics International Inc. Announces Update on its Oxycodone ER New Drug Application

Jul 24 2019, 5:00 PM EDT

Stock Overview

Symbol	IPCIF
Exchange	OTCQB
Market Cap	4.09m
Last Price	\$0.185
52-Week Range	\$0.145 - \$4.0984

Investor Relations

Intellipharmaeutics International Inc.
30 Worcester Road
Toronto, ON M9W 5X2
T: 416-798-3001
investors@intellipharmaeutics.com

09/20/2019 03:04 PM EDT

Management Team

Isa Odidi, Ph.D., MBA

Chairman, CEO, Co-Chief Scientific Officer (CSO)

Amina Odidi, Ph.D.

President, COO, Co-Chief Scientific Officer (CSO)

Greg Powell, CPA - CGA

Chief Financial Officer

Patrick N. Yat, Ph.D.

Vice President, Chemistry & Analytical Services

Christian Akyempon, B.Sc. (Honors), M.Sc., MBA

Vice President, Commercial Operations

Intellipharmaeutics International Inc.

30 Worcester Road
Toronto, ON M9W 5X2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 20-F and its quarterly reports. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.